Atlas Trials

Kidney Cancer With PBRM1/BAP1/VHL/SETD2 Mutations

1 clinical trials · Condition

Sort:Newest firstOldest first

◉ Watch Kidney Cancer With PBRM1/BAP1/VHL/SETD2 Mutations

RecordFirmDate
An Expanded Access Program to Axitinib is Available for Patients With Advanced Forms of Kidney Cancer (Ductal; Papillary; Chromophobic; Oncocytic) With Mutations in VHL, PBRM1 / BAP1, SETD2, VEGF) (NCT05941637)Lynkcell Europe

Track Kidney Cancer With PBRM1/BAP1/VHL/SETD2 Mutations automatically

Every clearance here is in the API, with alerts when new ones post.